Antibiotics used in this study	References for indications in sepsis	References for use in animal models
Daptomycin	• 4-6 mg/kg/day (Tompkins & Harnicar, 2008). • reviewed in (Trotman, Williamson, Shoemaker, & Salzer, 2005).	• Our study: 30 mg/kg • Experimental foreign body S.aureus infection (30mg/kg) (Vaudaux et al., 2003). = NB: Level of Plasma and tissue cage fluids at 1 h is 100 and 8 mg/L respectively. • *S. aureus* endocarditis (25-40mg/kg) (Sakoulas, Eliopoulos, Alder, & Thauvin-eliopoulos, 2003). = NB: dose selection was refered to as mimicking human dose.
Erythromycin	• 1-3 mg/kg/day (Nguyen et al., 2007). • reviewed in (Hawkyard & Koerner, 2007).	• Our study: 5 mg/kg. • 1-10mg/kg (McCormack, Snipes, Dillon, Yang, & Finn, 1990). • Laparotomy: 1mg/kg (De Winter et al., 1999).
imipenem	• Peritonitis: 500mg every 6 hours, 1000mg every 8 hours and 1000mg every 6 hours: Peritoneal fluid and plasma levels in patients in ICU peak is ~40min, but sufficient levels in 1h to act as anti-bacterial (Dahyot-Fizelier et al., 2010). • neonatal sepsis: 20 mg/kg (Lu, 2011). • Reviewed in (Legrand, Max, Schlemmer, Azoulay, & Gachot, 2011; Trotman et al., 2005).	• Our study: 20 mg/kg. • CLP model of sepsis: 20 mg/kg (Ghiselli et al., 2002).
Linezolid	• MRSA nosocomial pneumonia: 10-15 mg/kg, with half life of 3h in children and 5h in adults, reviewed in (Chiappini, Conti, Galli, & De Martino, 2010). • Reviewed in (Trotman et al., 2005).	• Our study: 25 mg/kg. • Model of intra-abdominal abscess: 25 mg/kg (Schülin, Thauvin-Eliopoulos, Moellering, & Eliopoulos, 1999).
Tigecycline	• Intra-abdominal infections: 100 mg iv, then 50mg i.v. every 12h (Stein & Craig, 2006). • Use of 12.5 – 300mg or 25-50 mg given every 12 h, and half-life of ~36 h, reviewed in (Noskin, 2005). • (Swoboda et al., 2008).	• Our study: 5 mg/kg. • *E. faecalis* peritonitis (mice): 5.7 mg/kg (Nannini, Pai, Singh, & Murray, 2003).

Tobramycin	• cystic fibrosis: 10 mg/kg/day (Aminimanizani, 2002). • sepsis: 5mg/kg/day (Gibson et al., 1993). • reviewed also in (Legrand et al., 2011).	• Our study: 25 mg/kg. • 25 mg/kg/day (Barza, Pinn, Tanguay, & Murray, 1978).
Vancomycin	• MRSA in children: 40-70 mg/kg/day (Frymoyer, Hersh, Coralic, Benet, & Guglielmo, 2010). • 15-20 mg/kg every 8-12 h (Broome & So, 2011). • reviewed also in (Legrand et al., 2011; Trotman et al., 2005).	• Our study: 70 mg/kg. • Endocarditis: 25 mg/kg i.p. every 8 h (Patel, Rouse, Piper, & Steckelberg, 2001). • *S. aureus*: 50 mg/kg/day (Murillo et al., 2009).

1. Aminimanizani, a. (2002). Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. *Journal of Antimicrobial Chemotherapy*, *50*(4), 553–559.
2. Barza, M., Pinn, V., Tanguay, P., & Murray, T. (1978). Nephrotoxicity of newer cephalosporins and aminoglycosides alone and in combination in a rat model. *The Journal of antimicrobial chemotherapy*, *4 Suppl A*, 59–68.
3. Broome, L., & So, T.-Y. (2011). An evaluation of initial vancomycin dosing in infants, children, and adolescents. *International journal of pediatrics*, *2011*, Article ID: 470364 (4 pages).
4. Chiappini, E., Conti, C., Galli, L., & De Martino, M. (2010). Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. *Clinical therapeutics*, *32*(1), 66–88.
5. Dahyot-Fizelier, C., Lefeuvre, S., Laksiri, L., Marchand, S., Sawchuk, R. J., Couet, W., & Mimoz, O. (2010). Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. *Clinical pharmacokinetics*, *49*(5), 323–34.
6. De Winter, B. Y., Boeckxstaens, G. E., De Man, J. G., Moreels, T. G., Schuurkes, J. a, Peeters, T. L., Herman, a G., et al. (1999). Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. *Gut*, *45*(5), 713–8.
7. Frymoyer, A., Hersh, A., Coralic, Z., Benet, L., & Guglielmo, B. J. (2010). Prediction of Vancomycin Pharmacodynamics in Children With Invasive Methicillin-Resistant *Staphylococcus aureus* Infections: A Monte Carlo Simulation. *Clin Ther*, *32*(3), 534–542.
8. Ghiselli, R., Giacometti, A., Cirioni, O., Mocchegiani, F., Viticchi, C., Scalise, G., & Saba, V. (2002). Cationic Peptides Combined with Betalactams Reduce Mortality from Peritonitis in Experimental Rat Model. *Journal of Surgical Research*, *108*(1), 107–111.
9. Gibson, J., Johnson, L., Snowdon, L., Joshua, D., Young, G., MacLeod, C., Sader, C., et al. (1993). Single daily ceftriaxone and tobramycin in the empirical

management of febrile neutropenic patients: a randomised trial. *International Journal of Hematology* (Vol. 58, pp. 63–72).
10. Hawkyard, C. V, & Koerner, R. J. (2007). The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. *The Journal of antimicrobial chemotherapy*, *59*(3), 347–58.
11. Legrand, M., Max, A., Schlemmer, B., Azoulay, E., & Gachot, B. (2011). The strategy of antibiotic use in critically ill neutropenic patients. *Annals of intensive care*, *1*(1), 22.
12. Lu, A. (2011). Neonatal Sepsis Caused by Gram-negative Bacteria in a Neonatal Intensive Care Unit : A Six Years Analysis, 253–257.
13. McCormack, a J., Snipes, R. G., Dillon, J. J., Yang, J. J., & Finn, W. F. (1990). Primary renovascular effects of erythromycin in the rat: relationship to cyclosporine nephrotoxicity. *Renal failure*, *12*(4), 241–8.
14. Murillo, O., Garrigós, C., Pachón, M. E., Euba, G., Verdaguer, R., Cabellos, C., Cabo, J., et al. (2009). Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant *Staphylococcus* aureus. *Antimicrobial agents and chemotherapy*, *53*(10), 4252–7.
15. Nannini, E. C., Pai, S. R., Singh, K. V, & Murray, B. E. (2003). Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model, *47*(2), 529–532.
16. Nguyen, N. Q., Mangoni, a a, Fraser, R. J., Chapman, M., Bryant, L., Burgstad, C., & Holloway, R. H. (2007). Prokinetic therapy with erythromycin has no significant impact on blood pressure and heart rate in critically ill patients. *British journal of clinical pharmacology*, *63*(4), 498–500.
17. Noskin, G. A. (2005). Tigecycline: a new glycylcycline for treatment of serious infections. *Clin Infect Dis*, *41*(Suppl 5), S303–S314.
18. Patel, R., Rouse, M. S., Piper, K. E., & Steckelberg, J. M. (2001). Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. *Antimicrob Agents Chemother*, *45*(2), 621–623.
19. Sakoulas, G., Eliopoulos, G. M., Alder, J., & Thauvin-eliopoulos, C. (2003). Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus, *47*(5), 1714–1718.
20. Schülin, T., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (1999). Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant *Enterococcus faecium*. *Antimicrobial agents and chemotherapy*, *43*(12), 2873–6.
21. Stein, G. E., & Craig, W. a. (2006). Tigecycline: a critical analysis. *Clinical infectious diseases*, *43*(4), 518–24.
22. Swoboda, S., Ober, M., Hainer, C., Lichtenstern, C., Seiler, C., Wendt, C., Hoppe-Tichy, T., et al. (2008). Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. *The Journal of antimicrobial chemotherapy*, *61*(3), 729–33.
23. Tompkins, N. H. C., & Harnicar, S. J. (2008). Prescribing Trends with Daptomycin (Cubicin) For the Treatment of Gram-Positive Infections Drug Utilization Evaluation : Daptomycin. *P & T*, *33*(5), 282-288.

24. Trotman, R. L., Williamson, J. C., Shoemaker, D. M., & Salzer, W. L. (2005). Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, *41*(8), 1159–66.
25. Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., & Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. *The Journal of antimicrobial chemotherapy*, *52*(1), 89–95.